<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00460239</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-08045-8</org_study_id>
    <secondary_id>5R01DA008045-08</secondary_id>
    <secondary_id>R01DA008045</secondary_id>
    <secondary_id>DPMCDA</secondary_id>
    <nct_id>NCT00460239</nct_id>
  </id_info>
  <brief_title>Buprenorphine's Dose Response Curve</brief_title>
  <official_title>Evaluation of Opioid Antagonist Activity in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a residential study that looks at the effects of buprenorphine in persons who abuse
      but are not dependent on opioids. Animal studies show that very high doses of buprenorphine
      produce less effects than mid-range doses. This suggests that buprenorphine can be a very
      safe medication. However, no studies in humans have tested higher doses in a similar way. The
      goal of this study is to show the effects of single doses of buprenorphine, across a range of
      doses, in persons who are not physically dependent on opioids (but do abuse opioids).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preclinical studies have demonstrated for a variety of measures that buprenorphine has a
      bell-shaped dose response curve. However, human studies with buprenorphine have not shown
      such an effect, although controlled studies have generally not tested higher acute doses of
      buprenorphine. Current clinical recommendations generally place an upper limit of daily
      buprenorphine dosing at 32 mg of sublingual tablets, although considerably higher acute doses
      have been administered to humans (primarily in clinical studies of less than daily dosing).
      Determining the relationship between higher doses of buprenorphine in humans and effects
      produced would be valuable; it would be scientifically interesting to demonstrate a
      bell-shaped curve in humans, and it would help guide clinical practice (for example, with
      respect to dosing, safety, and side effect considerations. The purpose of this study is to
      characterize the dose response curve for buprenorphine in humans, utilizing acute single
      doses of parenteral buprenorphine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Change From Baseline in Drug Effect Assessed by Visual Analog Scale (VAS)</measure>
    <time_frame>Each experimental test session (8 experimental test sessions assessed for up to 6-7 weeks)</time_frame>
    <description>Opioid agonist effects measured by peak change from baseline drug effect visual analog scale. Scores range from 0 (not all all) to 100 (extremely); higher scores indicate a stronger drug effect.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Psychomotor/Cognitive Performance Effects Assessed by Digit Symbol Substitution Test (DSST)</measure>
    <time_frame>Each experimental test session (8 experimental test sessions assessed for up to 6-7 weeks)</time_frame>
    <description>Digit Symbol Substitution Test (DSST) is a sub-test within the Wechsler Adult Intelligence Scale and is frequently used to assess psychomotor performance changes associated with drug effects. The higher the percent correct on this measure the better the performance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Psychomotor/Cognitive Performance Effects Assessed by Trails B</measure>
    <time_frame>Each experimental test session (8 experimental test sessions assessed for up to 6-7 weeks)</time_frame>
    <description>The Trails B task specifically measures set shifting and executive functioning within the Trail-Making Test. Part B consists of 25 circles distributed over a sheet of paper. Participants are asked to connect the circles in an ascending pattern, alternating between numbers and letters (i.e., 1-A-2-B-3-C, etc.). Results are reported as the number of seconds required to complete the task; therefore, higher scores reveal greater impairment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physiologic Effects as Assessed by Blood Pressure</measure>
    <time_frame>Each experimental test session (8 experimental test sessions assessed for up to 6-7 weeks)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Physiologic Effects as Assessed by Heart Rate</measure>
    <time_frame>Each experimental test session (8 experimental test sessions assessed for up to 6-7 weeks)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Physiologic Effects as Assessed by Body Temperature</measure>
    <time_frame>Each experimental test session (8 experimental test sessions assessed for up to 6-7 weeks)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Physiologic Effects as Assessed by Oxygen Saturation</measure>
    <time_frame>Each experimental test session (8 experimental test sessions assessed for up to 6-7 weeks)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Physiologic Effects as Assessed by Pupil Diameter</measure>
    <time_frame>Each experimental test session (8 experimental test sessions assessed for up to 6-7 weeks)</time_frame>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Opioid-related Disorders</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine 15</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine 30</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Buprenorphine 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Buprenorphine 16</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Buprenorphine 32</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Buprenorphine 48</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Buprenorphine 60</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine</intervention_name>
    <description>Intramuscular, doses (8, 16, 32, 48, 60 mg) are blind; administered up to 1-2 times per week.</description>
    <arm_group_label>Buprenorphine 8</arm_group_label>
    <arm_group_label>Buprenorphine 16</arm_group_label>
    <arm_group_label>Buprenorphine 32</arm_group_label>
    <arm_group_label>Buprenorphine 48</arm_group_label>
    <arm_group_label>Buprenorphine 60</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>Intramuscular; up to 1-2 times per week; doses (15, 30 mg) double blind</description>
    <arm_group_label>Morphine 15</arm_group_label>
    <arm_group_label>Morphine 30</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intramuscular; double blind; once per week</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. current opioid abuse but not physically dependent on opioids

        Exclusion Criteria:

          1. evidence of significant medical (e.g., insulin dependent diabetes) or psychiatric
             (e.g., schizophrenia) illness

          2. anemia defined as a hematocrit less than 30%

          3. females are required to provide a negative pregnancy test prior to study participation

          4. baseline electrocardiogram (ECG) showing prolongation of the corrected QT interval
             (QTc)

          5. current significant alcohol or sedative/hypnotic drug use

          6. Forced expiratory volume at one second (FEV1) of less than 50% at the time of
             screening

          7. applicants seeking treatment for their substance abuse will not be admitted to the
             study, and should be provided information about treatment services available
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric C Strain, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University (BPRU) Bayview Campus</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2007</study_first_submitted>
  <study_first_submitted_qc>April 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2007</study_first_posted>
  <results_first_submitted>August 18, 2012</results_first_submitted>
  <results_first_submitted_qc>January 11, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 3, 2017</results_first_posted>
  <last_update_submitted>January 11, 2017</last_update_submitted>
  <last_update_submitted_qc>January 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Opioid addiction</keyword>
  <keyword>Opioid dependence</keyword>
  <keyword>Buprenorphine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Analgesics, Opioid</mesh_term>
    <mesh_term>Buprenorphine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Condition 1</title>
          <description>Participants receive single doses of intramuscular (IM) test drugs; there were 9 possible test drugs (placebo [P], 2 doses of morphine [M], 5 doses of buprenorphine [B]), with at least 3 days between IM injections. For this condition, the order of dosing was (numbers represent doses in mg): B8, B16, B32, B48, B60, M15, M30, P.</description>
        </group>
        <group group_id="P2">
          <title>Condition 2</title>
          <description>Participants receive single doses of intramuscular (IM) test drugs; there were 9 possible test drugs (placebo [P], 2 doses of morphine [M], 5 doses of buprenorphine [B]), with at least 3 days between IM injections. For this condition, the order of dosing was (numbers represent doses in mg): B8, B16, B32, M15, B48, P, B60, M30.</description>
        </group>
        <group group_id="P3">
          <title>Condition 3</title>
          <description>Participants receive single doses of intramuscular (IM) test drugs; there were 9 possible test drugs (placebo [P], 2 doses of morphine [M], 5 doses of buprenorphine [B]), with at least 3 days between IM injections. For this condition, the order of dosing was (numbers represent doses in mg): B8, B16, B32, B48, M30, B60, P, M15.</description>
        </group>
        <group group_id="P4">
          <title>Condition 4</title>
          <description>Participants receive single doses of intramuscular (IM) test drugs; there were 9 possible test drugs (placebo [P], 2 doses of morphine [M], 5 doses of buprenorphine [B]), with at least 3 days between IM injections. For this condition, the order of dosing was (numbers represent doses in mg): B8, M15, B16, P, B32, M30, B48, B60.</description>
        </group>
        <group group_id="P5">
          <title>Condition 5</title>
          <description>Participants receive single doses of intramuscular (IM) test drugs; there were 9 possible test drugs (placebo [P], 2 doses of morphine [M], 5 doses of buprenorphine [B]), with at least 3 days between IM injections. For this condition, the order of dosing was (numbers represent doses in mg): B8, B16, M30, B32, P, B48, M15, B60.</description>
        </group>
        <group group_id="P6">
          <title>Condition 6</title>
          <description>Participants receive single doses of intramuscular (IM) test drugs; there were 9 possible test drugs (placebo [P], 2 doses of morphine [M], 5 doses of buprenorphine [B]), with at least 3 days between IM injections. For this condition, the order of dosing was (numbers represent doses in mg): M15, P, B8, M30, B16, B32, P, B48, B60.</description>
        </group>
        <group group_id="P7">
          <title>Condition 7</title>
          <description>Participants receive single doses of intramuscular (IM) test drugs; there were 9 possible test drugs (placebo [P], 2 doses of morphine [M], 5 doses of buprenorphine [B]), with at least 3 days between IM injections. For this condition, the order of dosing was (numbers represent doses in mg): M30, B8, P, B16, M15, B32, B48, B60.</description>
        </group>
        <group group_id="P8">
          <title>Condition 8</title>
          <description>Participants receive single doses of intramuscular (IM) test drugs; there were 9 possible test drugs (placebo [P], 2 doses of morphine [M], 5 doses of buprenorphine [B]), with at least 3 days between IM injections. For this condition, the order of dosing was (numbers represent doses in mg): P, M30, M15, B8, B16, B32, B48, B60.</description>
        </group>
        <group group_id="P9">
          <title>Condition 9</title>
          <description>Participants receive single doses of intramuscular (IM) test drugs; there were 9 possible test drugs (placebo [P], 2 doses of morphine [M], 5 doses of buprenorphine [B]), with at least 3 days between IM injections. For this condition, the order of dosing was (numbers represent doses in mg): M15, B8, B16, B32, M30, P, B48, B60.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>All Study Participants</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.2" spread="6.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Peak Change From Baseline in Drug Effect Assessed by Visual Analog Scale (VAS)</title>
        <description>Opioid agonist effects measured by peak change from baseline drug effect visual analog scale. Scores range from 0 (not all all) to 100 (extremely); higher scores indicate a stronger drug effect.</description>
        <time_frame>Each experimental test session (8 experimental test sessions assessed for up to 6-7 weeks)</time_frame>
        <population>Subjects who completed all test conditions.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo 0 mg</title>
          </group>
          <group group_id="O2">
            <title>Morphine 15 mg</title>
          </group>
          <group group_id="O3">
            <title>Morphine 30 mg</title>
          </group>
          <group group_id="O4">
            <title>Buprenorphine 8 mg</title>
          </group>
          <group group_id="O5">
            <title>Buprenorphine 16 mg</title>
          </group>
          <group group_id="O6">
            <title>Buprenorphine 32 mg</title>
          </group>
          <group group_id="O7">
            <title>Buprenorphine 48 mg</title>
          </group>
          <group group_id="O8">
            <title>Buprenorphine 60 mg</title>
          </group>
        </group_list>
        <measure>
          <title>Peak Change From Baseline in Drug Effect Assessed by Visual Analog Scale (VAS)</title>
          <description>Opioid agonist effects measured by peak change from baseline drug effect visual analog scale. Scores range from 0 (not all all) to 100 (extremely); higher scores indicate a stronger drug effect.</description>
          <population>Subjects who completed all test conditions.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.75" spread="22.41"/>
                    <measurement group_id="O2" value="27.25" spread="33.50"/>
                    <measurement group_id="O3" value="29.63" spread="43.29"/>
                    <measurement group_id="O4" value="58.25" spread="32.58"/>
                    <measurement group_id="O5" value="48.50" spread="41.19"/>
                    <measurement group_id="O6" value="40.25" spread="35.07"/>
                    <measurement group_id="O7" value="57.63" spread="40.41"/>
                    <measurement group_id="O8" value="41.63" spread="36.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Psychomotor/Cognitive Performance Effects Assessed by Digit Symbol Substitution Test (DSST)</title>
        <description>Digit Symbol Substitution Test (DSST) is a sub-test within the Wechsler Adult Intelligence Scale and is frequently used to assess psychomotor performance changes associated with drug effects. The higher the percent correct on this measure the better the performance.</description>
        <time_frame>Each experimental test session (8 experimental test sessions assessed for up to 6-7 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo 0 mg</title>
          </group>
          <group group_id="O2">
            <title>Morphine 15 mg</title>
          </group>
          <group group_id="O3">
            <title>Morphine 30 mg</title>
          </group>
          <group group_id="O4">
            <title>Buprenorphine 8 mg</title>
          </group>
          <group group_id="O5">
            <title>Buprenorphine 16 mg</title>
          </group>
          <group group_id="O6">
            <title>Buprenorphine 32 mg</title>
          </group>
          <group group_id="O7">
            <title>Buprenorphine 48 mg</title>
          </group>
          <group group_id="O8">
            <title>Buprenorphine 60 mg</title>
          </group>
        </group_list>
        <measure>
          <title>Psychomotor/Cognitive Performance Effects Assessed by Digit Symbol Substitution Test (DSST)</title>
          <description>Digit Symbol Substitution Test (DSST) is a sub-test within the Wechsler Adult Intelligence Scale and is frequently used to assess psychomotor performance changes associated with drug effects. The higher the percent correct on this measure the better the performance.</description>
          <units>percentage of correct answers</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.03" spread="10.21"/>
                    <measurement group_id="O2" value="91.60" spread="16.55"/>
                    <measurement group_id="O3" value="89.44" spread="18.33"/>
                    <measurement group_id="O4" value="90.91" spread="10.35"/>
                    <measurement group_id="O5" value="86.60" spread="19.98"/>
                    <measurement group_id="O6" value="83.17" spread="24.80"/>
                    <measurement group_id="O7" value="85.86" spread="19.21"/>
                    <measurement group_id="O8" value="77.99" spread="27.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Psychomotor/Cognitive Performance Effects Assessed by Trails B</title>
        <description>The Trails B task specifically measures set shifting and executive functioning within the Trail-Making Test. Part B consists of 25 circles distributed over a sheet of paper. Participants are asked to connect the circles in an ascending pattern, alternating between numbers and letters (i.e., 1-A-2-B-3-C, etc.). Results are reported as the number of seconds required to complete the task; therefore, higher scores reveal greater impairment.</description>
        <time_frame>Each experimental test session (8 experimental test sessions assessed for up to 6-7 weeks)</time_frame>
        <population>Subjects who completed all test conditions.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo 0 mg</title>
          </group>
          <group group_id="O2">
            <title>Morphine 15 mg</title>
          </group>
          <group group_id="O3">
            <title>Morphine 30 mg</title>
          </group>
          <group group_id="O4">
            <title>Buprenorphine 8 mg</title>
          </group>
          <group group_id="O5">
            <title>Buprenorphine 16 mg</title>
          </group>
          <group group_id="O6">
            <title>Buprenorphine 32 mg</title>
          </group>
          <group group_id="O7">
            <title>Buprenorphine 48 mg</title>
          </group>
          <group group_id="O8">
            <title>Buprenorphine 60 mg</title>
          </group>
        </group_list>
        <measure>
          <title>Psychomotor/Cognitive Performance Effects Assessed by Trails B</title>
          <description>The Trails B task specifically measures set shifting and executive functioning within the Trail-Making Test. Part B consists of 25 circles distributed over a sheet of paper. Participants are asked to connect the circles in an ascending pattern, alternating between numbers and letters (i.e., 1-A-2-B-3-C, etc.). Results are reported as the number of seconds required to complete the task; therefore, higher scores reveal greater impairment.</description>
          <population>Subjects who completed all test conditions.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.58" spread="0.84"/>
                    <measurement group_id="O2" value="1.51" spread="0.82"/>
                    <measurement group_id="O3" value="1.68" spread="1.15"/>
                    <measurement group_id="O4" value="1.57" spread="0.66"/>
                    <measurement group_id="O5" value="1.85" spread="1.39"/>
                    <measurement group_id="O6" value="1.42" spread="0.39"/>
                    <measurement group_id="O7" value="1.49" spread="0.53"/>
                    <measurement group_id="O8" value="1.46" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Physiologic Effects as Assessed by Blood Pressure</title>
        <time_frame>Each experimental test session (8 experimental test sessions assessed for up to 6-7 weeks)</time_frame>
        <population>Subjects who completed all test conditions.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo 0 mg</title>
          </group>
          <group group_id="O2">
            <title>Morphine 15 mg</title>
          </group>
          <group group_id="O3">
            <title>Morphine 30 mg</title>
          </group>
          <group group_id="O4">
            <title>Buprenorphine 8 mg</title>
          </group>
          <group group_id="O5">
            <title>Buprenorphine 16 mg</title>
          </group>
          <group group_id="O6">
            <title>Buprenorphine 32 mg</title>
          </group>
          <group group_id="O7">
            <title>Buprenorphine 48 mg</title>
          </group>
          <group group_id="O8">
            <title>Buprenorphine 60 mg</title>
          </group>
        </group_list>
        <measure>
          <title>Physiologic Effects as Assessed by Blood Pressure</title>
          <population>Subjects who completed all test conditions.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.11" spread="8.82"/>
                    <measurement group_id="O2" value="114.71" spread="10.34"/>
                    <measurement group_id="O3" value="119.21" spread="10.85"/>
                    <measurement group_id="O4" value="118.59" spread="15.15"/>
                    <measurement group_id="O5" value="111.42" spread="9.43"/>
                    <measurement group_id="O6" value="114.11" spread="14.84"/>
                    <measurement group_id="O7" value="119.18" spread="12.48"/>
                    <measurement group_id="O8" value="116.77" spread="11.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.85" spread="7.13"/>
                    <measurement group_id="O2" value="64.92" spread="8.18"/>
                    <measurement group_id="O3" value="66.72" spread="8.08"/>
                    <measurement group_id="O4" value="67.35" spread="7.62"/>
                    <measurement group_id="O5" value="61.82" spread="6.96"/>
                    <measurement group_id="O6" value="62.60" spread="9.33"/>
                    <measurement group_id="O7" value="65.73" spread="7.29"/>
                    <measurement group_id="O8" value="64.39" spread="7.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Physiologic Effects as Assessed by Heart Rate</title>
        <time_frame>Each experimental test session (8 experimental test sessions assessed for up to 6-7 weeks)</time_frame>
        <population>Subjects who completed all test conditions.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo 0 mg</title>
          </group>
          <group group_id="O2">
            <title>Morphine 15 mg</title>
          </group>
          <group group_id="O3">
            <title>Morphine 30 mg</title>
          </group>
          <group group_id="O4">
            <title>Buprenorphine 8 mg</title>
          </group>
          <group group_id="O5">
            <title>Buprenorphine 16 mg</title>
          </group>
          <group group_id="O6">
            <title>Buprenorphine 32 mg</title>
          </group>
          <group group_id="O7">
            <title>Buprenorphine 48 mg</title>
          </group>
          <group group_id="O8">
            <title>Buprenorphine 60 mg</title>
          </group>
        </group_list>
        <measure>
          <title>Physiologic Effects as Assessed by Heart Rate</title>
          <population>Subjects who completed all test conditions.</population>
          <units>beats/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.44" spread="7.56"/>
                    <measurement group_id="O2" value="70.56" spread="6.04"/>
                    <measurement group_id="O3" value="69.80" spread="8.19"/>
                    <measurement group_id="O4" value="71.22" spread="9.61"/>
                    <measurement group_id="O5" value="69.41" spread="8.19"/>
                    <measurement group_id="O6" value="66.44" spread="10.20"/>
                    <measurement group_id="O7" value="69.06" spread="6.86"/>
                    <measurement group_id="O8" value="67.51" spread="8.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Physiologic Effects as Assessed by Body Temperature</title>
        <time_frame>Each experimental test session (8 experimental test sessions assessed for up to 6-7 weeks)</time_frame>
        <population>Subjects who completed all test conditions.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo 0 mg</title>
          </group>
          <group group_id="O2">
            <title>Morphine 15 mg</title>
          </group>
          <group group_id="O3">
            <title>Morphine 30 mg</title>
          </group>
          <group group_id="O4">
            <title>Buprenorphine 8 mg</title>
          </group>
          <group group_id="O5">
            <title>Buprenorphine 16 mg</title>
          </group>
          <group group_id="O6">
            <title>Buprenorphine 32 mg</title>
          </group>
          <group group_id="O7">
            <title>Buprenorphine 48 mg</title>
          </group>
          <group group_id="O8">
            <title>Buprenorphine 60 mg</title>
          </group>
        </group_list>
        <measure>
          <title>Physiologic Effects as Assessed by Body Temperature</title>
          <population>Subjects who completed all test conditions.</population>
          <units>Degrees Fahrenheit</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.99" spread="5.41"/>
                    <measurement group_id="O2" value="87.43" spread="4.82"/>
                    <measurement group_id="O3" value="89.20" spread="3.91"/>
                    <measurement group_id="O4" value="89.76" spread="4.30"/>
                    <measurement group_id="O5" value="90.33" spread="3.84"/>
                    <measurement group_id="O6" value="89.11" spread="4.12"/>
                    <measurement group_id="O7" value="90.22" spread="4.25"/>
                    <measurement group_id="O8" value="90.62" spread="4.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Physiologic Effects as Assessed by Oxygen Saturation</title>
        <time_frame>Each experimental test session (8 experimental test sessions assessed for up to 6-7 weeks)</time_frame>
        <population>Subjects who completed all test conditions.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo 0 mg</title>
          </group>
          <group group_id="O2">
            <title>Morphine 15 mg</title>
          </group>
          <group group_id="O3">
            <title>Morphine 30 mg</title>
          </group>
          <group group_id="O4">
            <title>Buprenorphine 8 mg</title>
          </group>
          <group group_id="O5">
            <title>Buprenorphine 16 mg</title>
          </group>
          <group group_id="O6">
            <title>Buprenorphine 32 mg</title>
          </group>
          <group group_id="O7">
            <title>Buprenorphine 48 mg</title>
          </group>
          <group group_id="O8">
            <title>Buprenorphine 60 mg</title>
          </group>
        </group_list>
        <measure>
          <title>Physiologic Effects as Assessed by Oxygen Saturation</title>
          <population>Subjects who completed all test conditions.</population>
          <units>percentage of saturated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.81" spread="0.77"/>
                    <measurement group_id="O2" value="97.57" spread=".80"/>
                    <measurement group_id="O3" value="97.15" spread="0.84"/>
                    <measurement group_id="O4" value="96.94" spread="0.96"/>
                    <measurement group_id="O5" value="96.73" spread="1.07"/>
                    <measurement group_id="O6" value="96.37" spread="1.61"/>
                    <measurement group_id="O7" value="96.75" spread="1.30"/>
                    <measurement group_id="O8" value="96.49" spread="1.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Physiologic Effects as Assessed by Pupil Diameter</title>
        <time_frame>Each experimental test session (8 experimental test sessions assessed for up to 6-7 weeks)</time_frame>
        <population>Subjects who completed all test conditions.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo 0 mg</title>
          </group>
          <group group_id="O2">
            <title>Morphine 15 mg</title>
          </group>
          <group group_id="O3">
            <title>Morphine 30 mg</title>
          </group>
          <group group_id="O4">
            <title>Buprenorphine 8 mg</title>
          </group>
          <group group_id="O5">
            <title>Buprenorphine 16 mg</title>
          </group>
          <group group_id="O6">
            <title>Buprenorphine 32 mg</title>
          </group>
          <group group_id="O7">
            <title>Buprenorphine 48 mg</title>
          </group>
          <group group_id="O8">
            <title>Buprenorphine 60 mg</title>
          </group>
        </group_list>
        <measure>
          <title>Physiologic Effects as Assessed by Pupil Diameter</title>
          <population>Subjects who completed all test conditions.</population>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" spread="1.31"/>
                    <measurement group_id="O2" value="3.33" spread="0.87"/>
                    <measurement group_id="O3" value="2.74" spread="0.83"/>
                    <measurement group_id="O4" value="2.87" spread="1.19"/>
                    <measurement group_id="O5" value="2.73" spread="0.84"/>
                    <measurement group_id="O6" value="2.63" spread="0.79"/>
                    <measurement group_id="O7" value="2.61" spread="1.02"/>
                    <measurement group_id="O8" value="2.64" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected during time participants resided on the residential unit (target period of 6-7 weeks).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo Intervention</title>
        </group>
        <group group_id="E2">
          <title>Morphine Intervention</title>
        </group>
        <group group_id="E3">
          <title>Buprenorphine Intervention</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eric C. Strain, M.D.</name_or_title>
      <organization>Johns Hopkins University School of Medicine</organization>
      <phone>410-550-1191</phone>
      <email>ecsgss@aol.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

